Last reviewed · How we verify
Piperacillin/Tazobactam Continuous infusion
Piperacillin/tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation.
Piperacillin/tazobactam is a beta-lactam antibiotic combined with a beta-lactamase inhibitor that kills bacteria by inhibiting cell wall synthesis while protecting the antibiotic from enzymatic degradation. Used for Bacterial infections including pneumonia, intra-abdominal infections, and urinary tract infections, Febrile neutropenia in immunocompromised patients, Polymicrobial infections caused by beta-lactamase-producing organisms.
At a glance
| Generic name | Piperacillin/Tazobactam Continuous infusion |
|---|---|
| Also known as | Piprataz injection |
| Sponsor | Ain Shams University |
| Drug class | Beta-lactam/beta-lactamase inhibitor combination |
| Target | Penicillin-binding proteins (PBPs); beta-lactamases |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Piperacillin is an extended-spectrum penicillin that binds to penicillin-binding proteins and disrupts bacterial cell wall cross-linking, leading to cell lysis and death. Tazobactam is a beta-lactamase inhibitor that irreversibly binds to and inactivates beta-lactamases produced by resistant bacteria, preventing degradation of piperacillin and restoring its activity against beta-lactamase-producing organisms. Continuous infusion delivery maintains sustained bactericidal concentrations over time.
Approved indications
- Bacterial infections including pneumonia, intra-abdominal infections, and urinary tract infections
- Febrile neutropenia in immunocompromised patients
- Polymicrobial infections caused by beta-lactamase-producing organisms
Common side effects
- Diarrhea
- Nausea
- Rash
- Phlebitis at infusion site
- Headache
- Allergic reactions (including anaphylaxis in penicillin-sensitive patients)
Key clinical trials
- Subcutaneous Piperacillin/Tazobactam Compared With Intravenous Treatment (PHASE2)
- Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis (PHASE4)
- PK/PD of Extended-infusion Meropenem, Piperacillin-tazobactam and Cefepime in the Early Phase of Septic Shock (PHASE3)
- Beta-Lactams Dosing In Pneumonia in ICU in Patients Treated by Continuous Renal Replacement Therapy: the BLIPIC Study
- BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia (PHASE4)
- Therapeutic Drug Monitoring and Continuous Infusion of Beta-lactam Antibiotics in Patients With Bacteraemia (PHASE4)
- Are Standard Dosing Regimens of Piperacillin-Tazobactam Suitable in Critically Ill Patients With Open Abdomen and Negative Pressure Wound Therapy? A Population Pharmacokinetic Study.
- Population Pharmacokinetics and Dosage Individualization of Antibiotics in Elderly Patients
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: